Hemogenyx Pharmaceuticals PLC Announces Final Results for the Year Ended 31 December 2018 - 29/04/2019
Hemogenyx Pharmaceuticals plc ("Hemogenyx" or the "Company")(HEMO.L), the biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces its Final Results for the year ended 31 December 2018. It was an important year for Hemogenyx both scientifically and commercially as we progressed and diversified our product pipeline and commenced collaborations with several key pharmaceutical industry partners. Work on CDX antibodies is progressing well and we have initiated discussions with a global pharmaceutical company on a potential licensing deal. Additionally, we have been evaluating the use of CDX antibodies in combination with other blood cancer treatments and as a potential treatment for relapsed/refractory AML. Our collaborations with Orgenesis will accelerate the development of our Hu-PHEC cell therapy product and the adoption of Hemogenyx's AHC humanised mice, a new product line.